Impact of Inflammatory Indexes and Gene Scores in Prediction of Atrial Fibrillation (IERV)

Vrinnevi Hospital

Status: Enrolling

Conditions: Inflammation; Atrial Fibrillation; Genetic Predisposition to Disease

Treatments: Other: Blood sampling

Study type: Observational

Funder types: Other

Identifiers

NCT06399666

Dnr 2023-02252-01

Details and patient eligibility

About

Because of the high recurrence rates following electrical cardioversion and high morbidity in AF patients there is a need to explore prediction models for AF recurrence following ECV. Previous studies have primarily focused on high-sensitivity CRP (hsCRP), CRP, and IL-6, while other inflammatory indexes and gene scores might hold greater value.

This prospective cohort study is planning to include 182 patients with persistent atrial fibrillation, planned for electrical cardioversion, and >18 years at two medium-sized hospitals in Sweden. Blood samples will be collected prior to electrical cardioversion and at 7-, 30-, 90-, and 180-days follow-up. Atrial fibrillation recurrence will be evaluated at follow-up or upon patient request and diagnosed with 12-lead ECG.

An interim analysis will be conducted after more than 80 patients have been included. If the results from univariate and/or multivariable logistic regression on inflammatory markers and genetic expression regarding atrial fibrillation recurrence are significant, the study will be concluded.

Enrollment: 182 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Persistent atrial fibrillation (ICD-10 I48.1)
• Age over 18 years

Exclusion criteria

• Autoimmune disease
• Inflammatory diseases
• Acute or chronic liver dysfunction
• Ongoing infectious diseases
• Thyroid disorders
• Any other conditions known to impact inflammatory activity (including medication use and hematological diseases)

Trial design

182 participants in 1 patient group

Prospective cohort

Description:

Prospective cohort measuring the previously described biomarkers.

Treatment:

Other: Blood sampling